What are the key performance highlights of the newly developed subcutaneous glucose-powered fuel cell?

A research team from ETH Zurich in Switzerland has invented a novel fuel cell implant for treating type 1 diabetes. This miniature fuel cell generates electricity from excess blood glucose (blood sugar), powering implantable medical devices without requiring an external power source. The researchers recently published their findings in the German journal Advanced Materials, reporting that they integrated this battery with artificial beta-cell mimics to create a self-regulating device: excess glucose automatically drives insulin release, while the system powers itself electrically—achieving successful blood glucose control in mouse models of type 1 diabetes. Type 1 diabetes is an autoimmune disease that prevents the body from naturally producing insulin, causing blood sugar levels to rise excessively. In 2016, the same research team had tested a capsule implant containing synthetic beta cells. When stimulated by electricity or blue LED light, these cells autonomously secreted and released insulin, helping patients better manage their blood glucose. However, this earlier system lacked a viable power source. The current solution is a tea-bag–like fuel cell implant capable of converting surplus glucose—derived from carbohydrates and other foods—into electrical energy. This new fuel cell is slightly larger than a human fingernail and roughly the size of a tea bag. It is encased in nonwoven fabric and coated externally with alginate—a seaweed-derived substance. Its core component consists of copper-containing nanomaterial electrodes that break down glucose into gluconic acid and protons, thereby generating electricity. This generated current is used in conjunction with insulin-releasing capsules containing beta cells to trigger insulin secretion.

Are there any undisclosed cures for type 1 diabetes? Has the glucose-powered tea-bag–shaped implant successfully treated type 1 diabetes?

CRISPR gene-editing technology will further accelerate progress toward generating fully differentiated, insulin-producing, low-immunogenic pancreatic islet cells for T1D. VCTX210—a investigational allogeneic, immune-evasive, gene-edited, stem cell–derived therapy for T1D co-developed by two companies—aims to eliminate the need for exogenous insulin without requiring immunosuppression. A Phase 1 clinical trial evaluating VCTX210’s safety and tolerability in T1D patients has completed dosing. VCTX211 is another gene-edited, allogeneic, stem cell–derived candidate therapy for T1D, jointly developed by ViaCyte and CRISPR Therapeutics. Its clinical trial application has received approval from Health Canada, and its Phase 1/2 clinical trial is now underway, with patient recruitment and dosing in progress. Vertex stated that its latest agreement with CRISPR Therapeutics does not affect the ongoing VCTX211 Phase 1/2 trial. For more information on Vertex’s stem cell therapy for type 1 diabetes, please click the link below. Hope for curing T1D! Nanotechnology & stem cell transplantation with immune evasion—a perfect match with VX-880 Has hope for curing T1D been dashed? VX-880 stem cell therapy paused by the FDA; the first participant has already resumed insulin production. Generating energy from blood glucose Next, we discuss another promising future approach potentially capable of curing type 1 diabetes. Since its first investigation in 1968, the glucose fuel cell—which efficiently harnesses the body’s chemical energy and converts it into electrical charge—has long been a scientific goal. A research group at ETH Zurich has developed a novel fuel cell implant for treating type 1 diabetes. Crucially, it connects to the artificial beta cells designed by the same team in 2016—cells that successfully produce and release insulin when triggered. When combined with insulin-releasing artificial beta cells, this creates a fully autonomous system for regulating blood glucose levels, with potential future applications in diabetes treatment. The fuel cell itself resembles a tea bag slightly larger than a fingernail, covered in nonwoven fabric and coated with alginate—a seaweed-derived substance widely used in biomedicine due to its high biocompatibility. Once implanted subcutaneously, the alginate coating absorbs bodily fluids, allowing glucose to permeate the surface and enter the energy-generating core. Inside the battery, the team engineered a copper-based nanoparticle anode that breaks down glucose into gluconic acid and protons to generate electrical current.

ETH Zurich Researchers Develop Implant to Convert Blood Glucose in Mice

2 days ago

Researchers at ETH Zurich designed an implant converting excess blood glucose to gluconate via electrochemical reaction. The device aims to manage diabetes with fewer drugs by targeting the root cause.

cen

2026-07-22

ETH Zurich Develops Breathalyzer to Monitor Fat Burning

2026-10-23

ETH Zurich Researchers Develop Implant to Convert Blood Glucose in Mice

ETH Zurich Researchers Develop Implant to Convert Blood Glucose in Mice

FAQ